1-8 of 8
Ching-Shih Chen, Ph.D.
Close
Sort by
Journal Articles

OSU-2S, A Novel FTY720 derivative, Mediates Cytotoxicity In Chronic Lymphocytic Leukemia Through PKC Dependent Modulation of SHP1 Tyrosine Phosphatase

Rajeswaran Mani, DVM, Frank W Frissora, M.S., Ching-Shih Chen, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D
Journal: Blood
Blood (2011) 118 (21): 2499.
https://doi.org/10.1182/blood.V118.21.2499.2499
Published: 2011
Journal Articles

FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death

Lapo Alinari, MD., Ph.D., Emilia Mahoney, MD, PhD, John T. Patton, Xiaoli Zhang, PhD, MS, Lenguyen Huynh, Christian Tyler Earl, Rajeswaran Mani, DVM, Yicheng Mao, Bo Yu, Ph.D., William H. Towns, Ching-Shih Chen, Ph.D, David M. Goldenberg, Kristie A. Blum, MD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, Mette Ibba, PhD, Robert A. Baiocchi, M.D., Ph.D.
Journal: Blood
Blood (2011) 118 (21): 600.
https://doi.org/10.1182/blood.V118.21.600.600
Published: 2011
Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Joshua J Oaks, B.S., Christopher Walker, B.S., Ramasamy Santhanam, Ph.D, Carolyn Paisie, B.S., Anna Eiring, Ph.D, Bin Zhang, Ph.D, Bastianella Perazzona, Ph.D, Y. Ma, Charlene Mao, Guido Marcucci, MD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Stefano Volinia, MD, Jorge E. Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, Ph.D, Robert Bittman, Ph.D, Ching-Shih Chen, Ph.D, Ralph B. Arlinghaus, PhD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Ravi Bhatia, MD, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 515.
https://doi.org/10.1182/blood.V116.21.515.515
Published: 2010
Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2901.
https://doi.org/10.1182/blood.V116.21.2901.2901
Published: 2010
Journal Articles

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Paolo Neviani, PhD, Ramasamy Santhanam, Ph.D, Yihui Ma, B.S., Guido Marcucci, MD, John C. Byrd, MD, Ching-Shih Chen, Ph.D, Jorge Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 189.
https://doi.org/10.1182/blood.V112.11.189.189
Published: 2008
Journal Articles

Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.

Leslie A. Andritsos, MD, Amy J. Johnson, Ph.D., William Blum, M.D., Cheryl Kefauver, R.N., Farrukh Awan, M.D., Lisa L. Smith, Rosa Lapalombella, Da-Sheng Wang, Robert D. Knight, Ching-Shih Chen, Ph.D., John C. Byrd, M.D.
Journal: Blood
Blood (2007) 110 (11): 4727.
https://doi.org/10.1182/blood.V110.11.4727.4727
Published: 2007
Journal Articles

FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph 1 ALL Patients.

Ramasamy Santhanam, PhD, Paolo Neviani, D.Sci, Anna Eiring, B.S., Joshua Oaks, B.S., Mario Notari, D.Sci, Bradley W. Blaser, Ph.D., Shujun Liu, Ph.D, Rossana Trotta, Ph.D, Natarajan Muthusamy, Ph.D, Guido Marcucci, M.D., Carlo Gambacorti, M.D., Denis-Claude Roy, M.D., Michael A. Caligiuri, M.D., Clara D. Bloomfield, M.D., Ching-Shih Chen, Ph.D, John C. Byrd, M.D., Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 288.
https://doi.org/10.1182/blood.V108.11.288.288
Published: 2006
Journal Articles

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Qing Liu, MS, Xiaobin Zhao, M.S., Frank Frissora, M.S., Yihui Ma, M.S., Ramasamy Santhanam, Ph.D., Danilo Perrotti, M.D.,Ph.D., Ching-Shih Chen, Ph.D., James T. Dalton, Ph.D., John C. Byrd, M.D., Natarajan Muthusamy, DVM.,Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2095.
https://doi.org/10.1182/blood.V108.11.2095.2095
Published: 2006